UBS cuts Cytokinetics stock price target on valuation, keeps Buy
UBS reduced its price target for Cytokinetics (CYTK) to $104 from $115 but kept a Buy rating. The stock trades at $61.62, below the revised target and analyst consensus. UBS sees potential in Cytokinetics' drugs for hypertrophic cardiomyopathy. The company's shares have underperformed recently, down 7% in six months. Cytokinetics reported Q2 Myqorzo sales of $25.3M, exceeding estimates. Barclays raised its target to $110, while other analysts maintained Buy ratings with higher targets.
How this was made
The 30-second read
Why it matters
The downgrade may trigger short‑term selling pressure but long‑term upside remains tied to trial outcomes.
Market read
Analyst target revision is the primary new catalyst for CYTK, influencing short‑term price action.
What to watch
Upcoming trial data and Myqorzo sales growth could offset the target cut if results exceed expectations.
Background
UBS analyst report revises CYTK valuation amid recent sales beat and ongoing litigation.
Ticker impact
UBS lowered its price target for Cytokinetics to $104 from $115 while keeping a Buy rating, a fresh analyst downgrade disclosed in this article.
likely pressure as investors digest the lower valuation and target
Analyst target cuts are a direct catalyst; UBS is a respected house and the new target is well below current price, prompting potential sell‑offs.
Market effects
Biotech sector may see modest pullback as a peer receives a lower target.
U.S. market participants focused on small‑cap biotech may adjust exposure.
Limited to investors tracking CYTK and comparable biotech names.
Counterpoint
Some investors may view the lower target as an entry point given the stock's oversold RSI.
Key entities
- companyCytokinetics, Inc.
Biopharma developing Myqorzo for hypertrophic cardiomyopathy.
- analystUBS
Investment bank providing the revised price target.
